Jefferies Financial Group
AXSM icon

Jefferies Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Jefferies Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,000
Closed -$423K – 1621
2024
Q4 		$423K Buy
+5,000
New +$460K ﹤0.01% 1161

Other funds holding AXSM

Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 42.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Jefferies Financial Group's AXSM Position: Q3 2026 in Review

Jefferies Financial Group increased its Axsome Therapeutics (AXSM) stake by 22% in Q3 2026, buying an estimated $1.25M and bringing the position to 31,373 shares worth $5.78M. The position accounts for 0.04% of the portfolio, ranked #287.

Jefferies Financial Group first reported a position in AXSM in Q3 2023 and has held it in 9 quarters since. The position peaked at $44.8M in Q4 2023. 286 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Jefferies Financial Group held 31,373 shares of Axsome Therapeutics worth $5.78M as of Q3 2026.
  • Jefferies Financial Group bought 5,745 Axsome Therapeutics shares in Q3 2026, an estimated $1.25M.
  • Axsome Therapeutics made up 0.04% of Jefferies Financial Group's portfolio in Q3 2026, its #287 holding.
  • Jefferies Financial Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 9 quarters since.
  • Jefferies Financial Group's Axsome Therapeutics position peaked at $44.8M in Q4 2023.
  • 286 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Jefferies Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.